logo-loader
Arix Bioscience PLC

Arix Bioscience shares jump as largest investee firm Autolus files for proposed US IPO

Autolus, which was spun out from University College London in 2014, is aiming to develop next-generation CAR-T treatments that it hopes will have an edge over the first wave of anti-cancer therapies

Arix Bioscience
Aside from Arix Bioscience, its backers include Syncona and Woodford Investment Management

Arix Bioscience PLC (LON:ARIX) shares jumped on Wednesday as it revealed that its largest investee business, Autolus Therapeutics Limited has filed for a proposed initial public offering on Nasdaq in the United States.

Autolus, which is developing T-cell therapies for cancer treatments, has filed a registration statement with the US Securities and Exchange Commission (SEC) for an offering of American Depositary Shares (ADSs), with the pricing terms for the proposed IPO yet been determined.

READ: Arix Bioscience hoping to generate venture capital-style returns from the life sciences industry

Arix led the Series B financing of Autolus in March 2016, with Joe Anderson, Arix’s CEO, joining Autolus’s board of directors.

Autolus has since progressed from a pre-clinical to clinical stage company, with clinical trials currently ongoing for five programmes in six indications.

Autolus, which was spun out from University College London in 2014, is aiming to develop next-generation CAR-T treatments that it hopes will have an edge over the first wave of anti-cancer therapies. Aside from Arix Bioscience, its backers include Syncona and Woodford Investment Management.

In lunchtime trading, Arix’s shares in London were 6% higher at 211.0p.

Quick facts: Arix Bioscience PLC

Price: £1.19

Market: LSE
Market Cap: £161.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read